Developing drug-eluting implants requires careful formulation screening, especially when working with limited quantities of active pharmaceutical ingredients. This presentation shares a case study using Risperidone, where multiple polymeric carriers were evaluated for compatibility, stability, and release behavior. Each formulation underwent comprehensive characterization, including DSC, FTIR, SEM, and long-term dissolution testing over 80 days. From this data-driven screening, three candidates were selected for scale-up using hot-melt extrusion (HME). The resulting implants were compared to those made during early-stage development, demonstrating strong alignment in performance and structure. This talk emphasizes the value of early, material-efficient screening to guide formulation decisions and reduce development risk. It also illustrates how small-scale methods can reliably predict outcomes at manufacturing scale, enabling faster, smarter development of implantable drug delivery systems.
Learning Objectives:
Describe a systematic approach to formulation screening for drug-eluting implants.
Interpret key analytical data
Evaluate how early-stage prototypes compare to scaled-up implants produced via hot-melt extrusion
